Many in the industry might welcome the flexibility that led to positive outcomes for oral contraceptives. Still, it might be worth objectively assessing the factors contributing to the outcome.
Take the right learning from a situation that was mostly about ministerial intervention
February 28, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News -
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech -
4DMedical secures Stanford as first commercial site and expands AstraZeneca partnership in Brazil
October 23, 2025 - - Australian Biotech -
ImpediMed accelerates growth strategy on strong results and expanding market reach
October 23, 2025 - - Australian Biotech -
Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results
October 23, 2025 - - Australian Biotech -
Starpharma receives upfront payment from Genentech, launching oncology collaboration
October 23, 2025 - - Australian Biotech